ACM Global Central Lab announced the launch of a liquid nitrogen based dry-vapor shipping solution in collaboration with Cryoport, Inc.
After a six-month effort to validate both technological elements and international regulatory capabilities, ACM was able to confirm that Cryoport’s dry-vapor technology is in compliance with the stringent global regulatory standards and stable temperature profiles to ensure specimen viability. As part of ACM’s comprehensive validation effort, the company assessed the movement and temperature profile of almost 600 unique specimens over a multitude of shipping lanes, including international clinical trial hubs in India, China, Southeast Asia, and Europe. ACM is now offering this cold chain shipping solution at significant cost savings compared to dry ice shipping methods to its global customers.
The reusable CryoPort Express LN2 Dry Vapor Shipper is designed to meet the needs of clinical labs, diagnostic companies, research organizations, and the biotech and pharmaceutical industries by allowing tissue samples, blood, and other biological material to remain frozen at or below -150ºC for 10+ days, in contrast to the current industry practice of dry-ice packaging, which often requires re-icing during transit.
“ACM is proud to move this technology into production mode. With international courier costs consuming a significant portion of all global protocol budgets, we believe this new service offering from Cryoport can be an attractive alternative. Not only is the actual shipment more cost effective, the increased cost of adding more dry ice during transit to protect specimen integrity is eliminated,” said Tracy Hendershott, ACM Global’s vice president of clinical trials. “Cryoport has been extremely collaborative in complying with ACM’s stringent validation efforts, and now we look forward to sharing that benefit with our global clients.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
The State of the Opioid Epidemic
March 26th 2024In part 1 of this video interview, Greg Sturmer, co-founder and CEO of Elysium Therapeutics discusses the current state of opioid usage including how pain treatment is often mismanaged and how the industry can adopt greater safety standards in developing pain therapies.